BEV inhibits the vascular endothelial growth factor (VEGF), generating ADRs, such as arterial hypertension, thromboembolic events and gastrointestinal perforations, and negatively influencing the quality of life of patients [34,35]. Here, VEGFA is linked to Hypertension.